Literature DB >> 7603429

Pneumonia and influenza death rates--United States, 1979-1994.

.   

Abstract

The combined cause-of-death category pneumonia and influenza (P&I) (International Classification of Diseases, Ninth Revision, codes 480-487) ranks as the sixth leading cause of death in the United States following heart disease, cancer, stroke, unintentional injuries, and chronic obstructive pulmonary disease. Changes in the epidemiology of Streptococcus pneumoniae and other recognized respiratory pathogens, the increasing occurrence of drug-resistant microorganisms, and the detection of new respiratory pathogens have heightened awareness of the public health importance of severe respiratory infections. To characterize the epidemiology of P&I deaths in the United States, CDC further analyzed underlying and multiple cause-of-death mortality files for 1979-1994. This report summarizes the results of this analysis.

Entities:  

Mesh:

Year:  1995        PMID: 7603429

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  20 in total

1.  An exploratory spatial analysis of pneumonia and influenza hospitalizations in Ontario by age and gender.

Authors:  E J Crighton; S J Elliott; R Moineddin; P Kanaroglou; R E G Upshur
Journal:  Epidemiol Infect       Date:  2006-07-07       Impact factor: 2.451

2.  Objective computer-based assessment of valleculae residue--is it useful?

Authors:  Jill C Dyer; Paula Leslie; Michael J Drinnan
Journal:  Dysphagia       Date:  2008-03       Impact factor: 3.438

3.  Estimating the proportion of pneumonia attributable to pneumococcus in Kenyan adults: latent class analysis.

Authors:  Jukka Jokinen; J Anthony G Scott
Journal:  Epidemiology       Date:  2010-09       Impact factor: 4.822

4.  An aged host promotes the evolution of avirulent coxsackievirus into a virulent strain.

Authors:  Raina T Gay; Sarah Belisle; Melinda A Beck; Simin Nikbin Meydani
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-01       Impact factor: 11.205

5.  Limited impact of a multicenter intervention to improve the quality and efficiency of pneumonia care.

Authors:  Ethan A Halm; Carol Horowitz; Alan Silver; Alan Fein; Yosef D Dlugacz; Bruce Hirsch; Mark R Chassin
Journal:  Chest       Date:  2004-07       Impact factor: 9.410

6.  Validation of the Infectious Disease Society of America/American Thoracic Society 2007 guidelines for severe community-acquired pneumonia.

Authors:  Samuel M Brown; Barbara E Jones; Al R Jephson; Nathan C Dean
Journal:  Crit Care Med       Date:  2009-12       Impact factor: 7.598

7.  [Update to the Latin American Thoracic Association (ALAT) recommendations on community acquired pneumonia].

Authors: 
Journal:  Arch Bronconeumol       Date:  2004-08       Impact factor: 4.872

Review 8.  Targeted antioxidants as therapeutics for treatment of pneumonia in the elderly.

Authors:  Stefi F Lee; Rebecca Harris; Heather W Stout-Delgado
Journal:  Transl Res       Date:  2020-03-16       Impact factor: 7.012

9.  Efficacy and tolerability of sequential intravenous/oral moxifloxacin therapy in pneumonia: results of the first post-marketing surveillance study with intravenous moxifloxacin in hospital practice.

Authors:  J Barth; K Stauch; H Landen
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

Review 10.  Pneumococcal diversity: considerations for new vaccine strategies with emphasis on pneumococcal surface protein A (PspA).

Authors:  D E Briles; R C Tart; E Swiatlo; J P Dillard; P Smith; K A Benton; B A Ralph; A Brooks-Walter; M J Crain; S K Hollingshead; L S McDaniel
Journal:  Clin Microbiol Rev       Date:  1998-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.